Oppenheimer Assumes Gain Therapeutics at Outperform, Announces Price Target of $8
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Jay Olson has assumed coverage of Gain Therapeutics (NASDAQ:GANX) with an Outperform rating and set a price target of $8.
August 14, 2024 | 12:04 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Oppenheimer analyst Jay Olson has assumed coverage of Gain Therapeutics (NASDAQ:GANX) with an Outperform rating and set a price target of $8.
The Outperform rating and the price target of $8 from a reputable analyst at Oppenheimer is likely to positively influence investor sentiment and drive short-term price appreciation for GANX.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100